RFI

MENU

    RFI

    Drop in a message and we will reach out to you

    Get to know our history

    SciencePharma was established in 2004 in Warsaw. From that time, it is in dynamic process of development, constantly expanding number of satisfied clients from Poland and other countries, as well as scope of services. During years of business, we have become the leader in polish consultancy companies, which offer specialized and client-tailored consulting services for pharma industry.

    20 years of experience in the pharmaceutical market.

    SciencePharma started its operations with only a few team members and with time grew to 100 qualified experts ready for complex pharmaceutical projects. We are looking brightly into our future plans and ideas. Our next steps will be to expand further in the field of biotechnology drugs, ATMPs or cannabis, by taking part in more advanced project.

    2004

    Company foundation

    2006

    First successful national registration procedure

    2007

    Pharmacovigilance service

    2008

    Over 300 registration dossiers for the harmonization process (obligatory after PL joins the EU)

    2009

    GCP and GLP audits; first BEQ studies, dossier for biotech product

    2010

    EU-funded R&D projects

    2011

    First GMP audits

    2012

    First pre-clinical studies

    2013

    First clinical trials as a CRO and GCP system implementation for clinical trials

    2015

    First preparation of IMPD for ATMP

    2016

    First in the EU OTC switch with a proprietary diagnostic tool validated in a clinical trial

    2016

    First marketing authorization in the EU for enoxaparin biosimilar

    2018

    First dossier preparation for Cannabis

    2019

    First support in notification/ certification for medical device

    2020

    First online GMP audits

    2021

    Adjustment services with the challenges of the pharmaceutical industry resulting from Brexit

    Our history. What is now? Stethoscope, smartphone, cardiogram recording.
    Today

    Expanding operations on new EU and non-EU markets, development of Market Access services, further improvement in the subject of ATMP, nanotechnology and cannabis.